The thrombolysis and angioplasty in myocardial infarction (TAMI) trials: A decade of reperfusion strategies

Beginning with its inception in 1985, the TAMI group performed randomized clinical trials in both academic and nonacademic settings. The ten TAMI trials not only proved the viability of clinical research in a nontraditional environment, but also contributed significantly to the clinical investigation of acute myocardial infarction through small mechanistic trials. Despite having insufficient power to address overall survival and clinical outcome measures because of patient enrollments ranging from only 50-575 patients, the trials used similar entry criteria and follow-up measures, which permitted broader analyses of the prospectively collected dataset of randomized patients. This article reviews the history of the TAMI collaboration and discusses the findings of the individual trials as well as the contributions of larger analyses to our understanding of patient selection, prognosis, costs, and outcomes.

Duke Scholars

Author Erik Magnus Ohman Medicine, Cardiology